Breakpoint Therapeutics is a pioneering brand focused on developing targeted cancer therapies. Their cutting-edge approach involves modulating DNA damage response (DDR) pathways to effectively combat cancer cells while sparing healthy cells. By leveraging new insights and employing the concept of synthetic lethality, their drug candidates have the potential to increase the therapeutic window and deliver superior outcomes for patients with therapy-resistant and hard-to-treat cancers.

Backed by a strong network of research and development partners, including Evotec SE, Breakpoint Therapeutics is driven by foundational science and guided by class-leading expertise. They have garnered support from visionary life science investors, such as Medicxi, Taiho Ventures, Evotec, and BVF Partners. To learn more about Breakpoint Therapeutics and their groundbreaking approach to modulating DNA damage responses, you can contact them at their headquarters in Hamburg, Germany